In recent years, attention to cancer prevention has grown significantly, especially in often underestimated areas such as urinary tract cancers. According to specialists, more than 30 percent of solid tumors affect this very system, which performs an essential function of filtering toxic substances introduced into our bodies. For this very reason, early diagnosis is a key tool not only to save lives but also to reduce the impact on the health care system.

One of the leading proponents of this approach is Professor Ettore Mearini, professor of urology and director of the Urology Clinic with an oncology focus in Perugia, who stresses the importance of simple but regular checkups. The basis of prevention is a clear rule: screening every two years, especially in the 40-60 age group, which is considered most at risk.

Regarding kidney cancer, diagnosis can be made by a simple ultrasound scan. This noninvasive and easily accessible examination can detect any tumor masses while they are still small, less than 4 centimeters in size. Intervening at this early stage allows one to opt for conservative surgery, which consists of removing only the tumor without compromising the entire organ.

The results are extremely encouraging: 10-year survival exceeds 80% and, most importantly, kidney function is preserved, preventing future complications such as kidney failure or other related diseases.

Bladder cancer prevention also follows the two-year rule, but requires more attention in the presence of specific risk factors. These include smoking and occupational exposure to toxic substancessuch astar derivatives.

In these cases, a urine test should also be performed alongside the bladder ultrasound. If the persistent presence of blood in the urine is found, further investigation by urinary cytology is necessary. These are simple but essential examinations for early detection of abnormalities.

If diagnosed in time, bladder cancer can often be treated with endoscopic surgery, a minimally invasive technique that significantly reduces mortality and improves the patient's quality of life.

Another important chapter concerns prostate cancer, for which PSA testing is an essential early detection tool. Experts recommend starting screening as early as age 45 if there is a family history, or as early as age 50 if there is no predisposition. Again, early diagnosis makes a difference: survival at 10 years exceeds 80 percent and, with proper treatment, is up to 70 percent at 20 years. Numbers that testify to the significant progress made in urologic oncology in recent decades.

The message is clear: prevention is an investment in health. Regular checkups, simple examinations, and attention to risk factors can make the difference between a late diagnosis and a real chance of recovery.

Compared with two decades ago, the outlook for patients with urological cancers has improved markedly. However, the real breakthrough remains early diagnosis, made possible by increased awareness and accessible screening programs. Adopting the "two-year rule" might seem like a small gesture, but it actually represents a big step toward a longer and healthier life.